These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35946516)

  • 21. IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways.
    Cai W; Ma Y; Song L; Cao N; Gao J; Zhou S; Tang X
    BMC Cancer; 2023 Jan; 23(1):87. PubMed ID: 36698167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway.
    Sun Y; Zhang H; Meng J; Guo F; Ren D; Wu H; Jin X
    Cell Rep; 2022 Aug; 40(7):111194. PubMed ID: 35977495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extracellular vesicles derived from cancer-associated fibroblasts carry tumor-promotive microRNA-1228-3p to enhance the resistance of hepatocellular carcinoma cells to sorafenib.
    Zhang Y; Pan Q; Shao Z
    Hum Cell; 2023 Jan; 36(1):296-311. PubMed ID: 36424471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. JIB-04, a Pan-Inhibitor of Histone Demethylases, Targets Histone-Lysine-Demethylase-Dependent AKT Pathway, Leading to Cell Cycle Arrest and Inhibition of Cancer Stem-Like Cell Properties in Hepatocellular Carcinoma Cells.
    Lee J; Kim JS; Cho HI; Jo SR; Jang YK
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
    Wang M; Wang Z; Zhi X; Ding W; Xiong J; Tao T; Yang Y; Zhang H; Zi X; Zhou W; Huang G
    Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
    Lu M; Fei Z; Zhang G
    Biomed Pharmacother; 2018 Jan; 97():1282-1288. PubMed ID: 29156516
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting PI3K/Akt/mTOR Pathway Identifies Differential Expression and Functional Role of IL8 in Liver Cancer Stem Cell Enrichment.
    Kahraman DC; Kahraman T; Cetin-Atalay R
    Mol Cancer Ther; 2019 Nov; 18(11):2146-2157. PubMed ID: 31439713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circ_0004018 suppresses cell proliferation and migration in hepatocellular carcinoma via miR-1197/PTEN/PI3K/AKT signaling pathway.
    Wang H; Zhang Q; Cui W; Li W; Zhang J
    Cell Cycle; 2021 Oct; 20(20):2125-2136. PubMed ID: 34570663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MiR-30e-3p Influences Tumor Phenotype through
    Gramantieri L; Pollutri D; Gagliardi M; Giovannini C; Quarta S; Ferracin M; Casadei-Gardini A; Callegari E; De Carolis S; Marinelli S; Benevento F; Vasuri F; Ravaioli M; Cescon M; Piscaglia F; Negrini M; Bolondi L; Fornari F
    Cancer Res; 2020 Apr; 80(8):1720-1734. PubMed ID: 32015093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases.
    Gan G; Shi Z; Shangguan C; Zhang J; Yuan Y; Chen L; Liu W; Li B; Meng S; Xiong W; Mi J
    Theranostics; 2021; 11(12):6006-6018. PubMed ID: 33897895
    [No Abstract]   [Full Text] [Related]  

  • 31. Context dependent isoform specific PI3K inhibition confers drug resistance in hepatocellular carcinoma cells.
    Narci K; Kahraman DC; Koyas A; Ersahin T; Tuncbag N; Atalay RC
    BMC Cancer; 2022 Mar; 22(1):320. PubMed ID: 35331184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib.
    Niu LL; Cheng CL; Li MY; Yang SL; Hu BG; Chong CCN; Chan SL; Ren J; Chen GG; Lai PBS
    Cell Death Dis; 2018 Aug; 9(9):852. PubMed ID: 30154433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Chen KF; Chen HL; Tai WT; Feng WC; Hsu CH; Chen PJ; Cheng AL
    J Pharmacol Exp Ther; 2011 Apr; 337(1):155-61. PubMed ID: 21205925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positive feedback loop of FAM83A/PI3K/AKT/c-Jun induces migration, invasion and metastasis in hepatocellular carcinoma.
    Liu C; Peng X; Li Y; Liu S; Hou R; Zhang Y; Zuo S; Liu Z; Luo R; Li L; Fang W
    Biomed Pharmacother; 2020 Mar; 123():109780. PubMed ID: 31901550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
    Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miR-218 modulate hepatocellular carcinoma cell proliferation through PTEN/AKT/PI3K pathway and HoxA10.
    Xiao ZD; Jiao CY; Huang HT; He LJ; Zhao JJ; Lu ZY; Liu LX
    Int J Clin Exp Pathol; 2014; 7(7):4039-44. PubMed ID: 25120782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.
    Xia H; Ooi LL; Hui KM
    Hepatology; 2013 Aug; 58(2):629-41. PubMed ID: 23471579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis B virus X protein induces hepatic stem cell-like features in hepatocellular carcinoma by activating KDM5B.
    Wang X; Oishi N; Shimakami T; Yamashita T; Honda M; Murakami S; Kaneko S
    World J Gastroenterol; 2017 May; 23(18):3252-3261. PubMed ID: 28566884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oroxin B Induces Apoptosis by Down-Regulating MicroRNA-221 Resulting in the Inactivation of the PTEN/PI3K/AKT Pathway in Liver Cancer.
    Li N; Men W; Zheng Y; Wang H; Meng X
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31801250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.